Open Access
Med Sci (Paris)
Volume 38, Number 1, Janvier 2022
Page(s) 59 - 69
Section M/S Revues
Published online 21 January 2022
  1. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thromboembolism. BMJ 2001 ; 323 : 1–9. [Google Scholar]
  2. Martinez F, Ramirez I, Perez-Campos E, et al. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Cont Trprod. Health Care 2012 ; 17 : 7–29. [Google Scholar]
  3. Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, Canonico M. Hormonal contraceptives and venous thromboembolism: An epidemiological update. Best Pract Res Clin Endocrinol Metab 2013 Feb ; 27(1): 25–34. [CrossRef] [PubMed] [Google Scholar]
  4. Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013 ; 347 : f5298. [CrossRef] [PubMed] [Google Scholar]
  5. de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014 Mar; 3 : CD01081. [Google Scholar]
  6. Dragoman MV, Tepper NK, Fu R, et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynecol Obstet 2018 ; 1–8. [Google Scholar]
  7. Oedingen C, Scholz S, Razum O. Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: the role of the progestogen type and estrogen dose. Thromb Res 2018 ; May; 165 : 68–78. [CrossRef] [PubMed] [Google Scholar]
  8. Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 2011 ; 343 : d6423. [CrossRef] [PubMed] [Google Scholar]
  9. Martinelli I, Maino A, Abbattista M, et al. Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study. Thromb Res. 2016 May; 141 : 153–157. [CrossRef] [Google Scholar]
  10. Jordan W.. Pulmonary embolism. Lancet 1961 ; 278 : 1146–1147. [CrossRef] [Google Scholar]
  11. Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women : cohort study. BMJ 2016 ; 353 : i2002. [CrossRef] [PubMed] [Google Scholar]
  12. Heinemann K, Moehner S, et al. Cardiovascular safety in users of different combined oral contraceptives – final results from the INAS-SCORE study. Abstract FC-03. Eur J Contracept Reprod Health Care 2018 ; 23 : 1–143. [Google Scholar]
  13. Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception 2017 ; 95 : 130–139. [CrossRef] [PubMed] [Google Scholar]
  14. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive. users who are carriers of factor V Leiden mutation. Lancet 1994 ; 334 : 1453–1457. [CrossRef] [PubMed] [Google Scholar]
  15. Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The thrombosis : risk and economic assessment of thrombophilia Screening (TREATS) study. Thromb Haemost 2005 ; 94 : 17–25. [CrossRef] [PubMed] [Google Scholar]
  16. van Vlijmen EF, Wiewel-Verschueren S, Monster TB, Meijer K. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2016 ; 14 : 1393–1403. [CrossRef] [PubMed] [Google Scholar]
  17. Hugon-Rodin J, Horellou MH, Conard J, et al. Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism. Thromb Haemost 2018 ; 118 : 5922–928. [CrossRef] [PubMed] [Google Scholar]
  18. Khialani D, le Cessie S, Lijfering WM, et al. The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk. Br J Haematol 2020; 191(1) : 90–7. [CrossRef] [PubMed] [Google Scholar]
  19. Zöller B, Ohlsson H, Sundquist J, Sundquist K. Family history of venous thromboembolism is a risk factor for venous thromboembolism in combined oral contraceptive users: a nationwide case-control study. Thromb J 2015 ; 13 : 34. [CrossRef] [PubMed] [Google Scholar]
  20. van Vlijmen EF, Veeger NJ, Middeldorp S, et al. The impact of a male of female thrombotic family history on contraceptive counselling: a cohort study. J Thromb Haemost 2016 ; 14 : 1741–1748. [CrossRef] [PubMed] [Google Scholar]
  21. Rosing J, Curvers J, Tans G. Oral contraceptives, thrombosis and haemostasis. Eur J Obstet Gynecol reprod Biol 2001 ; 95 : 193–197. [CrossRef] [PubMed] [Google Scholar]
  22. Khialani D, Rosendaal F, Vlieg AVH. Hormonal Contraceptives and the Risk of Venous Thrombosis. Semin Thromb Hemost 2020; 46 : 865–71. [CrossRef] [PubMed] [Google Scholar]
  23. Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update 2014 ; 20 : 76–105. [CrossRef] [PubMed] [Google Scholar]
  24. Grandi G, Del Savio MC, Facchinetti F. The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism. Expert Rev Clin Pharmacol 2021; 14 : 211–24. [CrossRef] [PubMed] [Google Scholar]
  25. Plu-Bureau G, Hugon-Rodin J, Maitrot-Mantelet L, Canonico M. Hormonal contraceptives and arterial disease : an epidemiological update. Best Pract Res Clin Endocrinol Metab 2013 ; 27 : 35–45. [CrossRef] [PubMed] [Google Scholar]
  26. Roach RE, Helmerhorst FM, Lijfering WM, et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst rev 2015; CD011054. [PubMed] [Google Scholar]
  27. Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012 ; 366 : 2257–2266. [CrossRef] [PubMed] [Google Scholar]
  28. Champaloux SW, Tepper NK, Monsour M, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol 2017; 216 : 489.e1-e7. [CrossRef] [Google Scholar]
  29. Perol S, Hugon-Rodin J, Plu-Bureau G. Hypertension artérielle et contraception. Presse Med 2019 ; 48 : 1269–1283. [CrossRef] [PubMed] [Google Scholar]
  30. Park H, Kim K. Associations between oral contraceptive use and risks of hypertension and prehypertension in a cross-sectional study of Korean women. BMC Womens Health 2013 ; 21 : 13–39. [Google Scholar]
  31. Okoth K, Chandan JS, Marshall T, et al. Association between the reproductive health of young women and cardiovascular disease in later life : umbrella review. BMJ 2020; 371 : m3502. [CrossRef] [PubMed] [Google Scholar]
  32. Schürks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: systematic review and metaanalysis. BMJ 2009 ; 339 : b3914. [CrossRef] [PubMed] [Google Scholar]
  33. MacGregor EA. Contraception and headache. Headache 2013 ; 53 : 247–276. [CrossRef] [PubMed] [Google Scholar]
  34. Sacco S, Merki-Feld GS, Ægidius KL, et al. European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain 2017; 18: 108. Correction to: Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain 2018 ; 19 : 81. [CrossRef] [PubMed] [Google Scholar]
  35. Plu-Bureau G, Sabbagh E, Hugon-Rodin J. Contraception hormonale et risque vasculaire. RPC Contraception CNGOF [Hormonal contraception and vascular risk: CNGOF Contraception Guidelines]. Gynecol Obstet Fertil Senol 2018 ; 46 : 823–833. [PubMed] [Google Scholar]
  36. Iversen I, Sivasubraniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: Royal College of General Pratitioners’Oral Contraception Study. Am J Obstet Gynecol 2017; 216 : 580 e 1–582 e9. [Google Scholar]
  37. Morch LS, Skovlund CW, Hannaford PC, et al. Contemporary Hormonal Contraception and Risk of Breast Cancer. N Eng J Med 2017 ; 377 : 2228–2239. [CrossRef] [PubMed] [Google Scholar]
  38. Kumle M, Weiderpass E, Braaten T, et al. Use of oral contraceptives and breast cancer risk: the Norvegian-Swedish Women’s Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002 ; 11 : 1375–1381. [PubMed] [Google Scholar]
  39. Vessey M, Yeates D. Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception 2013 ; 88 : 678–683. [CrossRef] [PubMed] [Google Scholar]
  40. Gierisch JM, Coeytaux RR, Peragallo Urrutia R, et al. Cancer Epidemiol Biomarkers Prev 2013 ; 22 : 1931–1943. [CrossRef] [PubMed] [Google Scholar]
  41. Gadducci A, Cosio S, Fruzetti F. Estro-progestin Contraceptives and Risk of Cervical Cancer: A Debated Issue. Anticancer Res 2020; 40 : 5995–6002. [CrossRef] [PubMed] [Google Scholar]
  42. Iversen L, Fielding S, Lidegaard O, Hannaford PC. Contemporary hormonal contraception and cervical cancer in women of reproductive age. Int J Cancer 2021; 1–9. [Google Scholar]
  43. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Beral V, Doll R, Hermon C, Peto R, et al. ovarian cancer and oral contraceptives reanalysis of data from 45 studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 2008 ; 371 : 303–314. [CrossRef] [PubMed] [Google Scholar]
  44. Iversen L, Fielding S, Lidegaard O, et al. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. BMJ 2018 ; 362 : k3609. [CrossRef] [PubMed] [Google Scholar]
  45. Grimbizis GF, Tarlatzis BC. The use of hormonal contraception and its protective role against endometrial and ovarian cancer. Best Pract Research Clin Obstet Gynecol 2010 ; 24 : 29–38. [CrossRef] [Google Scholar]
  46. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 2015 ; 16 : 1061–1070. [CrossRef] [PubMed] [Google Scholar]
  47. Murphy N, Xu L, Zervoudakis A, et al. Reproductive and menstrual factors and colorectal cancer incidence in the Women’s Health Study Initiative observational study. Br J Cancer 2017 ; 116 : 117–125. [CrossRef] [PubMed] [Google Scholar]
  48. Luan NN, Wu L, Gong TT, et al. Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-analysis of epidemiological studies. Cancer Causes Control 2015 ; 26 : 65–78. [CrossRef] [PubMed] [Google Scholar]
  49. Pesatori AC, Carugno M, Consonni D, et al. Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO). Br JCancer 2013 ; 109 : 1954–1964. [CrossRef] [PubMed] [Google Scholar]
  50. Stapelfeld C, Dammann C, Maser E. Sex-specificity in lung cancer risk. Int J Cancer 2020; 146 : 2376–82. [CrossRef] [PubMed] [Google Scholar]
  51. Lethaby A, Wise MR, Weterings MA, et al. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev 2019; é(2) : CD000154. [Google Scholar]
  52. Hoaglin DC, Filonenko A, Glickman ME, et al. Use of mixed-treatment-comparison methods in estimating efficacy of treatments for heavy menstrual bleeding. Eur J Med Res 2013 ; 18 : 17. [CrossRef] [PubMed] [Google Scholar]
  53. American college of Ostetricians and gynecologists. Non contraceptive uses of hormonal contraceptives. Practice bulletin N° 110. Obstet Gynecol 2010 ; 115 : 206–218. [CrossRef] [PubMed] [Google Scholar]
  54. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhea. Cochrane database Syst Rev 2009; 4(4). [Google Scholar]
  55. Vercellini P, Eskenazi B, Consonni D, et al. oral contraceptives and risk of endometriosis: a systematic review and meta-analysis. Hum Reprod Update 2011 ; 17 : 159–170. [CrossRef] [PubMed] [Google Scholar]
  56. Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014 ; 29 : 400–412. [CrossRef] [PubMed] [Google Scholar]
  57. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 7 : CD004425. [Google Scholar]
  58. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath RBJOG 2017 ; 124 : 1501–1512. [CrossRef] [PubMed] [Google Scholar]
  59. Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998 ; 70 : 432–439. [CrossRef] [PubMed] [Google Scholar]
  60. Bottomley C, Bourne T. Diagnosis and management of ovarian cyst accidents. Best Pract Res Clin Obstet Gynaecol 2009 ; 23 : 711–724. [CrossRef] [PubMed] [Google Scholar]
  61. Rohan TE, Miller AB. A cohort study of oral contraceptive use and risk of benign breast disease. Int J Cancer 1999 ; 19 ; 82: 191–196. [CrossRef] [PubMed] [Google Scholar]
  62. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004 ; 190 : S5–22. [CrossRef] [PubMed] [Google Scholar]
  63. Reed S, Koro C, DiBello J, et al. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism. Eur J Contracept Reprod Health Care 2021; 26 : 439–46. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.